TCF7 and head and neck squamous cell carcinoma: These findings indicated that ICB therapy in combination with Treg deletion might serve as a new strategy to achieve a stronger T cell immune response in the TIME when designing immunotherapy regimens for patients with HNSCC, especially for those with TCF1+Texprog/TCF1−Texterm ratios lower than 0.6.